Digital repository of Slovenian research organisations

Show document
A+ | A- | Help | SLO | ENG

Title:Cannabinoids and triple-negative breast cancer treatment
Authors:ID Dobovišek, Luka (Author)
ID Borštnar, Simona (Author)
ID Debeljak, Nataša (Author)
ID Kranjc Brezar, Simona (Author)
Files:URL URL - Source URL, visit https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1386548/full
 
.pdf PDF - Presentation file, download (1,03 MB)
MD5: 94085E57E4C165B8D20A7131A0D384EB
 
Language:English
Typology:1.02 - Review Article
Organization:Logo OI - Institute of Oncology
Abstract:Triple-negative breast cancer (TNBC) accounts for about 10-20% of all breast cancer cases and is associated with an unfavorable prognosis. Until recently, treatment options for TNBC were limited to chemotherapy. A new successful systemic treatment is immunotherapy with immune checkpoint inhibitors, but new tumor-specific biomarkers are needed to improve patient outcomes. Cannabinoids show antitumor activity in most preclinical studies in TNBC models and do not appear to have adverse effects on chemotherapy. Clinical data are needed to evaluate efficacy and safety in humans. Importantly, the endocannabinoid system is linked to the immune system and immunosuppression. Therefore, cannabinoid receptors could be a potential biomarker for immune checkpoint inhibitor therapy or a novel mechanism to reverse resistance to immunotherapy. In this article, we provide an overview of the currently available information on how cannabinoids may influence standard therapy in TNBC.
Keywords:triple-negative breast cancer, breast cancer, cancer treatment, cannabinoids
Publication status:Published
Publication version:Version of Record
Submitted for review:15.02.2024
Article acceptance date:15.07.2024
Publication date:08.08.2024
Place of publishing:Basel
Publisher:Frontiers Media SA
Year of publishing:2024
Number of pages:str. 1-13
Numbering:Vol. 15
Source:Basel, Switzerland
PID:20.500.12556/DiRROS-20455 New window
UDC:618.1
ISSN on article:1664-3224
DOI:10.3389/fimmu.2024.1386548 New window
COBISS.SI-ID:204044547 New window
Copyright:by Authors
Note:Nasl. z nasl. zaslona; Opis vira z dne 9. 8. 2024;
Publication date in DiRROS:18.09.2024
Views:4
Downloads:2
Metadata:XML RDF-CHPDL DC-XML DC-RDF
:
Copy citation
  
Share:Bookmark and Share


Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:Frontiers in immunology
Shortened title:Front. immunol.
Publisher:Frontiers Research Foundation
ISSN:1664-3224
COBISS.SI-ID:30774233 New window

Document is financed by a project

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:P3-0003-2022
Name:Razvoj in ovrednotenje novih terapij za zdravljenje malignih tumorjev

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:J3-3062-2021
Name:Avtologni imunohibridomi in napredno zdravljenje trojno negativnega raka dojk stadijev II in III

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.

Secondary language

Language:Slovenian
Keywords:trojno negativni rak dojke, rak dojke, onkološko zdravljenje, kanabinoidi


Back